Measurement of nuchal translucency and the prenatal diagnosis of down syndrome

Obstetrics and Gynecology

Volumn 114, Issue 4, 2009, Pages 829-838

  Del Carmen Saucedo, Mónica ^a,b   Devigan, Catherine ^a   Vodovar, Veronique ^a   Lelong, Nathalie ^a   Goffinet, François ^a   Khoshnood, Babak ^a  

^a INSERM   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FETUS; FETUS DEATH; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REGISTER; SCREENING; SECOND TRIMESTER PREGNANCY; SENSITIVITY ANALYSIS; SERUM;

ADULT; ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; EARLY DIAGNOSIS; ESTRIOL; FEMALE; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; SENSITIVITY AND SPECIFICITY;

EID: 70349690000     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181b6f251     Document Type: Article

References (36)

1. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 1990; 336:1133.
2. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-869
3. Nicolaides KH, Brizot ML, Snijders RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994;101:782-786
4. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-346
5. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: A prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219-225
6. Mol BW, Lijmer JG, van der Meulen J, Pajkrt E, Bilardo CM, Bossuyt PM. Effect of study design on the association between nuchal translucency measurement and Down syndrome. Obstet Gynecol 1999;94:864-869
7. Malone FD, D'Alton ME; Society for Maternal-Fetal Medicine. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003;102:1066-1079
8. Mooney RA, Peterson CJ, French CA, Saller DN Jr, Arvan DA. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome. Obstet Gynecol 1994;84:298-303.
9. Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361: 835-836
10. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-77.
11. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353: 2001-2011
12. Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S, Meyberg H, et al. Screening for trisomy 21 by fetal nuchal translucency and maternal age: A multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 2001;18:645-648
13. Prefumo F, Thilaganathan B. Agreement between predicted risk and prevalence of Down syndrome in first trimester nuchal translucency screening. Prenat Diagn 2002;22:917-918
14. Wellesley D, Boyle T, Barber J, Howe DT. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region. BMJ 2002;325:15.
15. Smith-Bindman R, Chu P, Bacchetti P, Waters JJ, Mutton D, Alberman E. Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes. Am J Obstet Gynecol 2003;189:980-985
16. Khoshnood B, De Vigan C, Vodovar V, Goujard J, Goffinet F. A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000. BJOG 2004;111:485-490
17. Muller PR, Cocciolone R, Haan EA, Wilkinson C, Scott H, Sage L, et al. Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005. Am J Obstet Gynecol 2007;196: 315 e1-7.
18. de Vigan C, Khoshnood B, Cadio E, Vodovar V, Goffinet F. Prenatal diagnosis and prevalence of Down syndrome in the Parisian population, 2001-2005 [in French]. Gynecol Obstet Fertil 2008;36:146-150
19. Boyd PA, Devigan C, Khoshnood B, Loane M, Garne E, Dolk H. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG 2008;115:689-696
20. Ayme S. Value of registries in decision making in public health: the example of trisomy 21 [in French]. Rev Epidemiol Sante Publique 1996;44:S82-9.
21. Arreté du 29 Octobre 1991 modifiant la nomenclature des actes de biologie mé dicale. Journal Officiel 1991;14952.
22. Arreté du 23 Janvier 1997 modifiant l'arreté du 3 Avril 1985 fixant la nomenclature des actes de biolo gie mé dicale. Journal Officiel 1997;26;1365.
23. Dé cret no 2006-909 du 21 Juillet 2006 relatif à l'accré ditation de la qualité de la pratique professionnelle des médecins et des équipes mé dicales exerçant en établissements de santé . Journal Officiel 2006;23;11029.
24. Ville Y. 'Ceci n'est pas une echographie': A plea for quality assessment in prenatal ultrasound. Ultrasound Obstet Gynecol 2008;31:1-5.
25. Robbins AS, Chao SY, Fonseca VP. What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes. Ann Epidemiol 2002;12:452-454
26. Koenker R, Hallock K. Quantile regression. J Econ Perspect 2001;15:143-156
27. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modeling. Appl Stat 1994;43:429-467
28. Kornman LH, Wortelboer MJ, Beekhuis JR, Morssink LP, Mantingh A. Women's opinions and the implications of firstversus second-trimester screening for fetal Down's syndrome. Prenat Diagn 1997;17:1011-1018
29. Mulvey S, Wallace EM. Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. BJOG 2000;107:1302-1305
30. Marteau TM. Prenatal testing: towards realistic expectations of patients, providers and policy makers. Ultrasound Obstet Gynecol 2002;19:5-6.
31. Institut Européen des génomutations. Registre centre-est de malformations congé nitales. Données 2003. Dysplasie 2004; 23-25
32. EUROCAT. European surveillance of congenital anomalies. Prevalence data tables (1980 -2006). Available at: http://www. eurocat.ulster.ac.uk/pubdata/ index.html. Retrieved April 7, 2008.
33. Mansfield C, Hopfer S, Marteau TM. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: A systematic literature review. European Concerted Action: DADA (Decision- making after the diagnosis of a fetal abnormality). Prenat Diagn 1999;19:808-812
34. Haute Autorité de Santé (HAS). É valuation des straté gies de dé pistage de la trisomie 21. Available at: http://www.hassante. fr/portail/jcms/c-540874/evaluation-des-strategiesde- depistage-de-la-trisomie-21. Retrieved February 11, 2008.
35. Rozenberg P, Malagrida L, Cuckle H, Durand-Zaleski I, Nisand I, Audibert F, et al. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(-1)-17(+0) weeks: A prospective study. Hum Reprod 2002;17:1093-1098
36. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn 2003;23:833-836